PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Protein arginine methyltransferase 5 (PRMT5) has been implicated as a key modulator of lymphomagenesis. Whether PRMT5 has overt oncogenic function in the context of leukemia/lymphoma and whether it represents a therapeutic target remains to be established. We demonstrate that inactivation of PRMT5 inhibits colony-forming activity by multiple oncogenic drivers, including cyclin D1, c-MYC, NOTCH1, and MLL-AF9. Furthermore, we demonstrate that PRMT5 overexpression specifically cooperates with cyclin D1 to drive lymphomagenesis in a mouse model, revealing inherent neoplastic activity. Molecular analysis of lymphomas revealed that arginine methylation of p53 selectively suppresses expression of crucial proapoptotic and antiproliferative target genes, thereby sustaining tumor cell self-renewal and proliferation and bypassing the need for the acquisition of inactivating p53 mutations. Critically, analysis of human tumor specimens reveals a strong correlation between cyclin D1 overexpression and p53 methylation, supporting the biomedical relevance of this pathway. SIGNIFICANCE: We have identified and functionally validated a crucial role for PRMT5 for the inhibition of p53-dependent tumor suppression in response to oncogenic insults. The requisite role for PRMT5 in the context of multiple lymphoma/leukemia oncogenic drivers suggests a molecular rationale for therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of the enzymes targeted, particularly lysine and arginine methyltransferases, have non-histone substrates”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [182]
Experimental — accuracy not yet measuredIn the citing paper
“Moreover, certain cyclin D mutants or C-terminally truncated variants encoded by an alternatively spliced mRNA (D1b) that lacks the Thr-286 codon are retained in the nucleus during S phase and are proposed to confer a neo-oncogenic function that triggers DNA re-replication, aneuploidy, and tumorigenesis (59-61).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“The tumor suppressor properties of p53 have been linked to its function as a transcription factor that regulates the expression of target genes linked with cell cycle arrest, apoptosis, senescence and DNA repair (25, 26).”
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
An Oncogene-Induced DNA Damage Model for Cancer Development
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851 · cited 1×
“p53 is the central regulator of cell fate following numerous stresses including genotoxic stress and oncogene activation (23, 24).”
InfluentialProtein Arginine Methylation in Mammals: Who, What, and Why
Bedford, M. T., & Clarke, S. G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.013 · Cited by 1,792 · cited 1×
“3 INTRODUCTION Arginine methylation is becoming increasingly appreciated as an important mechanism of post-transcriptional control (1).”
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 2×
“Data demonstrating that mutant p53 alleles frequently have neopmorphic activities and thus do not equate with p53 deletion support this conclusion (28).”
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 2×
“The retention of wild-type p53 is generally associated with the loss of key effectors such as p19 ARF (p14 ARF in human cells) or with the overexpression of MDM2 (18, 40-42).”
Self-citationA novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Bedford, M. T., & Richard, S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.003 · Cited by 1,099 · cited 1×
“Proteins targeted by arginine methylation contribute to a variety of cellular processes including transcriptional regulation, chromatin regulation, RNA processing and DNA damage repair (2-4).”
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · cited 1×
“Cyclin D1, together with its binding partners cyclin dependent kinase 4 and 6 (CDK4/6), forms an active complex that promotes cell cycle progression by phosphorylating and inactivating the retinoblastoma protein (14).”
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · cited 3×
“The retention of wild-type p53 is generally associated with the loss of key effectors such as p19 ARF (p14 ARF in human cells) or with the overexpression of MDM2 (18, 40-42).”
Xiong, Y., Connolly, T., Futcher, B., & Beach, D. (1991) · Cell · doi:10.1016/0092-8674(91)90100-d · Cited by 685
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2716 · Cited by 609 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Pal, S., Vishwanath, S. N., Erdjument-Bromage, H., Tempst, P., & Sif, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9630-9645.2004 · Cited by 592
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541 · cited 1×
“The physiological importance of arginines R333, 335 and 337 in the regulation of p53 function is further emphasized by their mutation in Li Fraumeni families that present a wide spectrum of tumors (43, 44).”
Zhao, Q., Rank, G., Tan, Y. T., Li, H., Moritz, R. L., Simpson, R. J., Cerruti, L., Curtis, D. J., Patel, D. J., Allis, C. D., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1568 · Cited by 535 · cited 2×
“PRMT5-dependent dimethylation of histone H4 arginine 3 (H4R3) is associated with transcriptional repression (5-7).”
Alt, J. R., Cleveland, J. L., Hannink, M., & Diehl, J. A. (2000) · Genes & Development · doi:10.1101/gad.854900 · Cited by 535 · cited 1×
“Cyclin D1 nuclear export and polyubiquitylation depend upon phosphorylation of a specific threonine residue (Thr-286) (15).”
Self-citationDistinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533 · cited 1×
“p53 is the central regulator of cell fate following numerous stresses including genotoxic stress and oncogene activation (23, 24).”
InfluentialArginine methylation regulates the p53 response
Jansson, M., Durant, S. T., Cho, E.-C., Sheahan, S., Edelmann, M., Kessler, B., & La Thangue, N. B. (2008) · Nature Cell Biology · doi:10.1038/ncb1802 · Cited by 462 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
DNA damage checkpoints in stem cells, ageing and cancer
Sperka, T., Wang, J., & Rudolph, K. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3420 · Cited by 393 · cited 1×
“The tumor suppressor properties of p53 have been linked to its function as a transcription factor that regulates the expression of target genes linked with cell cycle arrest, apoptosis, senescence and DNA repair (25, 26).”
Molecular pathogenesis of mantle cell lymphoma
Jares, P., Colomer, D., & Campo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61272 · Cited by 382 · cited 11×
“In this model, D1T286A expression is targeted to the lymphoid compartment by the immunoglobulin enhancer, thereby providing an expression pattern analogous to that observed in human mantle cell lymphoma (MCL) (18).”
InfluentialBranscombe, T. L., Frankel, A., Lee, J.-H., Cook, J. R., Yang, Z.-H., Pestka, S., & Clarke, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105412200 · Cited by 362 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex
Lin, D. I., Barbash, O., Kumar, K. G. S., Weber, J. D., Harper, J. W., Klein-Szanto, A. J. P., Rustgi, A., Fuchs, S. Y., & Diehl, J. A. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.007 · Cited by 349
Self-citationVagin, V. V., Wohlschlegel, J., Qu, J., Jonsson, Z., Huang, X., Chuma, S., Girard, A., Sachidanandam, R., Hannon, G. J., & Aravin, A. A. (2009) · Genes & Development · doi:10.1101/gad.1814809 · Cited by 313 · cited 1×
“However, PRMT5 also targets multiple soluble proteins, including components of the spliceosome, PIWI proteins (8, 9), RelA (10), EGFR (11), E2f1 (12) and p53 (13), thereby potentially impacting multiple cellular signaling events.”
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 281 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Versatility of PRMT5-induced methylation in growth control and development
Karkhanis, V., Hu, Y.-J., Baiocchi, R. A., Imbalzano, A. N., & Sif, S. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.09.001 · Cited by 280 · cited 1×
“Although high levels of PRMT5 are associated with increased proliferation (36), mechanistic insights into its contribution will be critical to determine its potential as a therapeutic target.”
Wang, L., Pal, S., & Sif, S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00923-08 · Cited by 259 · cited 2×
“Proteins targeted by arginine methylation contribute to a variety of cellular processes including transcriptional regulation, chromatin regulation, RNA processing and DNA damage repair (2-4).”
Yang, Y., McBride, K. M., Hensley, S., Lu, Y., Chedin, F., & Bedford, M. T. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.01.011 · Cited by 252 · cited 1×
“Proteins targeted by arginine methylation contribute to a variety of cellular processes including transcriptional regulation, chromatin regulation, RNA processing and DNA damage repair (2-4).”
Self-citationXu, K., Shimelis, H., Linn, D. E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.021 · Cited by 248
Aggarwal, P., Vaites, L. P., Kim, J. K., Mellert, H., Gurung, B., Nakagawa, H., Herlyn, M., Hua, X., Rustgi, A. K., McMahon, S. B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.012 · Cited by 242 · cited 12×
“Since endogenous MEP50 levels remain stable after D1T286A and PRMT5 transduction (Fig 1H), we co-expressed either wild type MEP50 or MEP50T5A (an alanine mutation previously shown to make PRMT5/MEP50 complexes refractory to regulation by D1/CDK4 (5) with D1T286A/PRMT5.”
InfluentialSelf-citationPRMT5 dimethylates R30 of the p65 subunit to activate NF-κB
Wei, H., Wang, B., Miyagi, M., She, Y., Gopalan, B., Huang, D.-B., Ghosh, G., Stark, G. R., & Lu, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311784110 · Cited by 237
Arginine methylation of Piwi proteins catalysed by dPRMT5 is required for Ago3 and Aub stability
Kirino, Y., Kim, N., de Planell-Saguer, M., Khandros, E., Chiorean, S., Klein, P. S., Rigoutsos, I., Jongens, T. A., & Mourelatos, Z. (2009) · Nature Cell Biology · doi:10.1038/ncb1872 · Cited by 237 · cited 1×
“However, PRMT5 also targets multiple soluble proteins, including components of the spliceosome, PIWI proteins (8, 9), RelA (10), EGFR (11), E2f1 (12) and p53 (13), thereby potentially impacting multiple cellular signaling events.”
Hsu, J.-M., Chen, C.-T., Chou, C.-K., Kuo, H.-P., Li, L.-Y., Lin, C.-Y., Lee, H.-J., Wang, Y.-N., Liu, M., Liao, H.-W., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2158 · Cited by 236 · cited 2×
“However, PRMT5 also targets multiple soluble proteins, including components of the spliceosome, PIWI proteins (8, 9), RelA (10), EGFR (11), E2f1 (12) and p53 (13), thereby potentially impacting multiple cellular signaling events.”
Replication licensing and cancer — a fatal entanglement?
Blow, J. J., & Gillespie, P. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2500 · Cited by 228 · cited 1×
“The loss of Cul4A/B ultimately leads to overexpression of Cdt1, a key component of the replication licensing machinery (39).”
Arginine methylation controls growth regulation by E2F‐1
Cho, E., Zheng, S., Munro, S., Liu, G., Carr, S. M., Moehlenbrink, J., Lu, Y., Stimson, L., Khan, O., Konietzny, R., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.17 · Cited by 216 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Yan, F., Alinari, L., Lustberg, M. E., Katherine Martin, L., Cordero-Nieves, H. M., Banasavadi-Siddegowda, Y., Virk, S., Barnholtz-Sloan, J., Bell, E. H., Wojton, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0884 · Cited by 180 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
Xu-Monette, Z. Y., Medeiros, L. J., Li, Y., Orlowski, R. Z., Andreeff, M., Bueso-Ramos, C. E., Greiner, T. C., McDonnell, T. J., & Young, K. H. (2012) · Blood · doi:10.1182/blood-2011-11-366062 · Cited by 179 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Self-citationIdentification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1
Benzeno, S., Lu, F., Guo, M., Barbash, O., Zhang, F., Herman, J. G., Klein, P. S., Rustgi, A. K., & Diehl, J. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209644 · Cited by 167 · cited 1×
“The clinical relevance of mutations that specifically disrupt phosphorylation-dependent degradation and nuclear export of cyclin D1 is highlighted by their occurrence in human cancers (21, 22).”
Self-citationArginine Methylation-Dependent Reader-Writer Interplay Governs Growth Control by E2F-1
Zheng, S., Moehlenbrink, J., Lu, Y.-C., Zalmas, L.-P., Sagum, C. A., Carr, S., McGouran, J. F., Alexander, L., Fedorov, O., Munro, S., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.039 · Cited by 147 · cited 2×
“However, PRMT5 also targets multiple soluble proteins, including components of the spliceosome, PIWI proteins (8, 9), RelA (10), EGFR (11), E2f1 (12) and p53 (13), thereby potentially impacting multiple cellular signaling events.”
TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance
Peller, S., & Rotter, V. (2003) · Human Mutation · doi:10.1002/humu.10190 · Cited by 142 · cited 1×
“In contrast, hematological malignancies exhibit a low frequency of p53 mutation (29, 30), implicating the existence of alternative mechanisms for bypassing p53-dependent tumor suppression.”
Cyclin D1 gene (CCND1) mutations in endometrial cancer
Moreno‐Bueno, G., Rodríguez, S., Sánchez‐Estévez, C., Hardisson, D., Sarrió, D., Prat, J., Cigudosa, J. C., Matías‐Guiu, X., & Palacios, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206868 · Cited by 136 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Aggarwal, P., Lessie, M. D., Lin, D. I., Pontano, L., Gladden, A. B., Nuskey, B., Goradia, A., Wasik, M. A., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2007) · Genes & Development · doi:10.1101/gad.1586007 · Cited by 132 · cited 1×
“MYC – ICN + PRMT5 1 2 3 4 1 2 3 4 5 1 2 3 4 5 meR-p53 IgG control Normal (13-12521)”
Self-citationExpression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma
Gladden, A. B., Woolery, R., Aggarwal, P., Wasik, M. A., & Diehl, J. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209147 · Cited by 131 · cited 5×
“Since neither of these mechanisms was observed in D1T286A-driven tumors (16); data herein), we considered alternative mechanisms for bypassing p53 function.”
InfluentialSelf-citationChung, J., Karkhanis, V., Tae, S., Yan, F., Smith, P., Ayers, L. W., Agostinelli, C., Pileri, S., Denis, G. V., Baiocchi, R. A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.510669 · Cited by 93 · cited 1×
“In point of fact, PRMT5 inhibition can induce lymphoma cell death (45); and has also been suggested as a therapeutic target for glioblastoma (46).”
Acetylation of the DNA Binding Domain Regulates Transcription-independent Apoptosis by p53
Sykes, S. M., Stanek, T. J., Frank, A., Murphy, M. E., & McMahon, S. B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.026096 · Cited by 85 · cited 1×
“Tumor suppression by p53 can reflect either transcription-dependent (nuclear) activities and/or transcription-independent (cytoplasmic) activities (27, 33).”
Cheung, K. J., Horsman, D. E., & Gascoyne, R. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07739.x · Cited by 74 · cited 10×
“Immunohistochemical staining of lymph-node sections from human MCL patients revealed a marked increase of p53-me2 relative to normal lymph node ( Fig.”
InfluentialChiang, M. Y., Shestova, O. E., Xu, L., Aster, J. C., & Pear, W. S. (2012) · Blood · doi:10.1182/blood-2012-03-416503 · Cited by 59 · cited 1×
“Bone marrow transplantation (BMT) experiments were performed as previously described (47).”
Genetic Alterations in Esophageal Cancer
Okano, J., Snyder, L. C., & Rustgi, A. K. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:131 · Cited by 29
Self-citationVaites, L. P., Lian, Z., Lee, E. K., Yin, B., DeMicco, A., Bassing, C. H., & Diehl, J. A. (2013) · Oncogene · doi:10.1038/onc.2012.577 · Cited by 22 · cited 4×
“Analysis of early-stage tumors reveals that nuclear accumulation of D1T286A/CDK4 triggers DNA damage and activation of the ATM–CHK2–p53 checkpoint pathway, which leads to p53-dependent apoptosis ( 16 , 19 , 20 ).”
InfluentialSelf-citation
Cited by
Arginine Methylation: The Coming of Age
Blanc, R. S., & Richard, S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.003 · Cited by 1,054
“This crosstalk between H4R3me2a and H3K9/14Ac was reported to be present in various biological processes from cell differentiation to the response to cocaine (Li et al., 2015c).”
BackgroundInfluentialTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
“More recent work revealed that cyclin D1-CDK4 can inactivate p53 through PRMT5-dependent p53 methylation, thereby permitting tumor progression while maintaining wild-type p53 [40, 102].”
BackgroundInfluentialSelf-citationp53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Metadata
- Authors
- Li, Y., Chitnis, N., Nakagawa, H., Kita, Y., Natsugoe, S., Yang, Y., Li, Z., Wasik, M., Klein-Szanto, A. J. P., Rustgi, A. K., & Diehl, J. A.
- Affiliations
- University of Pennsylvania (US)
- Abramson Cancer Center (US)
- Kagoshima University (JP)
- Medical University of South Carolina (US)
- 7Fox Chase Cancer Center, Philadelphia, Pennsylvania.
- Corresponding author
- Diehl, J. Alan
- ORCID
- Venue
- Cancer Discovery
- Published
- 2015-03-01
- Volume
- 5
- Issue
- 3
- Pages
- 288-303
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4355177
- OpenAlex
- W2137003359
- Cited by
- 143
- References
- 49
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 19 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 17 · 2017: 12 · 2016: 12 · 2015: 6
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA098101, CA11360, R01CA093237)
- National Institute of Allergy and Infectious Diseases (R01AI070603)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050306)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- PRMT5, protein arginine methyltransferase, lymphomagenesis, cyclin D1, c-Myc, Notch1, MLL-AF9, leukemia, lymphoma, tumor self-renewal, therapeutic target
- MeSH terms
- Animals, Arginine, Cell Transformation, Neoplastic, Enzyme Activation, Humans, Lymphoma, Methylation, Mutation, Oncogenes, Phosphorylation, Protein-Arginine N-Methyltransferases, Transcription Factors, Leukemia, T-Cell, Cluster Analysis, Tumor Suppressor Protein p53, Lymphoma, T-Cell, Apoptosis, Cyclin D1, Amino Acid Substitution, Gene Expression Profiling, Adaptor Proteins, Signal Transducing, Cyclin-Dependent Kinase 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.